Unicycive Therapeutics is rated Buy with a risk-adjusted fair value of $6.97 per share, suggesting nearly 95% upside from current prices. The company's lead drug, OLC, targets hyperphosphatemia in chronic kidney disease dialysis patients, with a key FDA decision expected by March 25, 2027, after resolving manufacturing issues. Despite holding $61.4 million in cash, the company may need to raise additional capital for commercialization, potentially doubling its share count and diluting existing shareholders. Major risks include regulatory setbacks, a securities fraud lawsuit, and reliance on successful third-party manufacturing inspections.
Unicycive Therapeutics is noted for a nearly 95% upside potential priced against dilution and regulatory risks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 31, 2026 15:21 WIB: out of 150 US health stocks, 40 rose and 108 fell. Notable movers include DNA at USD 11.23 with a -11.85% change and 83% buy order activity, IOVA at USD 8.48 down 11.30% with 90% buy orders, and BTSG at USD 66.89 up 11.08% with 62% buy orders.
Bitcoin's whitepaper, published 18 years ago by Satoshi Nakamoto, proposed a decentralized payment system without trusted intermediaries. This anniversary comes as Binance faces a $6.3 billion cryptocurrency wallet breach, highlighting ongoing risks ...
Antero Midstream secured a $377 million settlement related to a water treatment plant dispute, significantly lowering its debt ratio to below 3.0. This financial improvement, combined with Antero Resources' resumed growth and strong Q3 performance, e...
On October 30, U.S. spot Bitcoin ETFs experienced $643.33 million in net outflows, marking their largest single-day withdrawal since June 25. BlackRock's IBIT and Fidelity's FBTC led the outflows, accounting for about 67.6% of the total withdrawals. ...
Uniswap (UNI), a popular cryptocurrency, saw its price increase by 4.5% over the past 24 hours, reaching $7.00. This price movement indicates renewed investor interest or positive market sentiment around UNI. Such changes can influence trading decisi...
Phreesia reported a 10.4% year-over-year revenue increase in Q2 to $129.5 million, driven mainly by growth in payment solutions after acquiring AccessOne. However, subscription revenue declined, and growth in network solutions remains crucial for the...
